APO Research
Talk to an analyst

APO RESEARCH · REPORT

Radiopharmaceuticals in Nuclear Medicine

Compare research editions
View pricing & licenses

Selected research

Industry Research

Radiopharmaceuticals in Nuclear Medicine Industry Research Report 2026

26 December 2025124 pages

Choose your research edition.

Industry ResearchRadiopharmaceuticals in Nuclear Medicine Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Radiopharmaceuticals in Nuclear Medicine Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Radiopharmaceuticals in Nuclear Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Radiopharmaceuticals in Nuclear Medicine Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Radiopharmaceuticals in Nuclear Medicine Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Radiopharmaceuticals in Nuclear Medicine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Radiopharmaceuticals in Nuclear Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Radiopharmaceuticals in Nuclear Medicine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Radiopharmaceuticals in Nuclear Medicine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Radiopharmaceuticals in Nuclear Medicine include Aurobindo Pharma, Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, Mundipharma and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Radiopharmaceuticals in Nuclear Medicine market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Radiopharmaceuticals in Nuclear Medicine Market by Company

Aurobindo Pharma

Bracco Imaging

Cardinal Health

Curium Pharma

GE Healthcare

Jubilant Pharma

Lantheus

Mundipharma

Novartis

SIEMENS

Bayer

Dongcheng

Eli Lilly

China Isotope & Radiation

Radiopharmaceuticals in Nuclear Medicine Segment by Type

Diagnostic Radiopharmaceuticals

Therapy Radiopharmaceuticals

Radiopharmaceuticals in Nuclear Medicine Segment by Application

Oncology

Cardiology

Other

Radiopharmaceuticals in Nuclear Medicine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceuticals in Nuclear Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceuticals in Nuclear Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceuticals in Nuclear Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Radiopharmaceuticals in Nuclear Medicine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Radiopharmaceuticals in Nuclear Medicine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Radiopharmaceuticals in Nuclear Medicine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Radiopharmaceuticals in Nuclear Medicine Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Radiopharmaceuticals in Nuclear Medicine Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Manufacturers (2021-2026) Table 8. Global Radiopharmaceuticals in Nuclear Medicine Revenue of Manufacturers (2021-2026) Table 9. Global Radiopharmaceuticals in Nuclear Medicine Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Radiopharmaceuticals in Nuclear Medicine Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Radiopharmaceuticals in Nuclear Medicine Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Radiopharmaceuticals in Nuclear Medicine, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Radiopharmaceuticals in Nuclear Medicine, Product Type & Application Table 14. Global Radiopharmaceuticals in Nuclear Medicine Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Radiopharmaceuticals in Nuclear Medicine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Aurobindo Pharma Company Information Table 19. Aurobindo Pharma Business Overview Table 20. Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 22. Aurobindo Pharma Recent Developments Table 23. Bracco Imaging Company Information Table 24. Bracco Imaging Business Overview Table 25. Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 27. Bracco Imaging Recent Developments Table 28. Cardinal Health Company Information Table 29. Cardinal Health Business Overview Table 30. Cardinal Health Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Cardinal Health Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 32. Cardinal Health Recent Developments Table 33. Curium Pharma Company Information Table 34. Curium Pharma Business Overview Table 35. Curium Pharma Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Curium Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 37. Curium Pharma Recent Developments Table 38. GE Healthcare Company Information Table 39. GE Healthcare Business Overview Table 40. GE Healthcare Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. GE Healthcare Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 42. GE Healthcare Recent Developments Table 43. Jubilant Pharma Company Information Table 44. Jubilant Pharma Business Overview Table 45. Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 47. Jubilant Pharma Recent Developments Table 48. Lantheus Company Information Table 49. Lantheus Business Overview Table 50. Lantheus Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Lantheus Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 52. Lantheus Recent Developments Table 53. Mundipharma Company Information Table 54. Mundipharma Business Overview Table 55. Mundipharma Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Mundipharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 57. Mundipharma Recent Developments Table 58. Novartis Company Information Table 59. Novartis Business Overview Table 60. Novartis Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Novartis Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 62. Novartis Recent Developments Table 63. SIEMENS Company Information Table 64. SIEMENS Business Overview Table 65. SIEMENS Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. SIEMENS Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 67. SIEMENS Recent Developments Table 68. Bayer Company Information Table 69. Bayer Business Overview Table 70. Bayer Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Bayer Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 72. Bayer Recent Developments Table 73. Dongcheng Company Information Table 74. Dongcheng Business Overview Table 75. Dongcheng Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Dongcheng Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 77. Dongcheng Recent Developments Table 78. Eli Lilly Company Information Table 79. Eli Lilly Business Overview Table 80. Eli Lilly Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Eli Lilly Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 82. Eli Lilly Recent Developments Table 83. China Isotope & Radiation Company Information Table 84. China Isotope & Radiation Business Overview Table 85. China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Product Portfolio Table 87. China Isotope & Radiation Recent Developments Table 88. Global Radiopharmaceuticals in Nuclear Medicine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 89. Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2021-2026) & (K Units) Table 90. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region (2021-2026) Table 91. Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2027-2032) & (K Units) Table 92. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region (2027-2032) Table 93. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2021-2026) & (US$ Million) Table 94. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Region (2021-2026) Table 95. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2027-2032) & (US$ Million) Table 96. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Region (2027-2032) Table 97. North America Radiopharmaceuticals in Nuclear Medicine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. North America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2026) & (K Units) Table 99. North America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2027-2032) & (K Units) Table 100. North America Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2021-2026) & (US$ Million) Table 101. North America Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2027-2032) & (US$ Million) Table 102. Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2026) & (K Units) Table 104. Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country (2027-2032) & (K Units) Table 105. Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2021-2026) & (US$ Million) Table 106. Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2027-2032) & (US$ Million) Table 107. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2026) & (K Units) Table 109. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Country (2027-2032) & (K Units) Table 110. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2021-2026) & (US$ Million) Table 111. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2027-2032) & (US$ Million) Table 112. South America Radiopharmaceuticals in Nuclear Medicine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. South America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2026) & (K Units) Table 114. South America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2027-2032) & (K Units) Table 115. South America Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2021-2026) & (US$ Million) Table 116. South America Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2027-2032) & (US$ Million) Table 117. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2026) & (K Units) Table 119. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Country (2027-2032) & (K Units) Table 120. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2021-2026) & (US$ Million) Table 121. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2027-2032) & (US$ Million) Table 122. Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2021-2026) & (K Units) Table 123. Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2027-2032) & (K Units) Table 124. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2021-2026) Table 125. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2027-2032) Table 126. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2021-2026) & (US$ Million) Table 127. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2027-2032) & (US$ Million) Table 128. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Type (2021-2026) Table 129. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Type (2027-2032) Table 130. Global Radiopharmaceuticals in Nuclear Medicine Price by Type (2021-2026) & (US$/Unit) Table 131. Global Radiopharmaceuticals in Nuclear Medicine Price by Type (2027-2032) & (US$/Unit) Table 132. Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2021-2026) & (K Units) Table 133. Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2027-2032) & (K Units) Table 134. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2021-2026) Table 135. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2027-2032) Table 136. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2021-2026) & (US$ Million) Table 137. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2027-2032) & (US$ Million) Table 138. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Application (2021-2026) Table 139. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Application (2027-2032) Table 140. Global Radiopharmaceuticals in Nuclear Medicine Price by Application (2021-2026) & (US$/Unit) Table 141. Global Radiopharmaceuticals in Nuclear Medicine Price by Application (2027-2032) & (US$/Unit) Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. Radiopharmaceuticals in Nuclear Medicine Distributors List Table 145. Radiopharmaceuticals in Nuclear Medicine Customers List Table 146. Radiopharmaceuticals in Nuclear Medicine Industry Trends Table 147. Radiopharmaceuticals in Nuclear Medicine Industry Drivers Table 148. Radiopharmaceuticals in Nuclear Medicine Industry Restraints Table 149. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Radiopharmaceuticals in Nuclear Medicine Product Image Figure 5. Global Radiopharmaceuticals in Nuclear Medicine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Radiopharmaceuticals in Nuclear Medicine Market Size (2021-2032) & (US$ Million) Figure 7. Global Radiopharmaceuticals in Nuclear Medicine Sales (2021-2032) & (K Units) Figure 8. Global Radiopharmaceuticals in Nuclear Medicine Average Price (US$/Unit) & (2021-2032) Figure 9. Diagnostic Radiopharmaceuticals Product Image Figure 10. Therapy Radiopharmaceuticals Product Image Figure 11. Oncology Product Image Figure 12. Cardiology Product Image Figure 13. Other Product Image Figure 14. Global Radiopharmaceuticals in Nuclear Medicine Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Radiopharmaceuticals in Nuclear Medicine, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Radiopharmaceuticals in Nuclear Medicine Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Radiopharmaceuticals in Nuclear Medicine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Radiopharmaceuticals in Nuclear Medicine Sales by Region in 2025 Figure 20. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region in 2025 Figure 21. North America Radiopharmaceuticals in Nuclear Medicine Market Size by Country in 2025 Figure 22. North America Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country (2021-2032) Figure 23. North America Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Country (2021-2032) Figure 24. United States Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Radiopharmaceuticals in Nuclear Medicine Market Size by Country in 2025 Figure 28. Europe Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country (2021-2032) Figure 29. Europe Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Country (2021-2032) Figure 30. Germany Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Market Size by Country in 2025 Figure 41. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Country (2021-2032) Figure 43. China Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Radiopharmaceuticals in Nuclear Medicine Market Size by Country in 2025 Figure 52. South America Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country (2021-2032) Figure 53. South America Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Country (2021-2032) Figure 54. Brazil Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Colombia Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Size by Country in 2025 Figure 59. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country (2021-2032) Figure 60. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Country (2021-2032) Figure 61. Egypt Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. South Africa Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Israel Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Türkiye Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. GCC Countries Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2021-2032) Figure 67. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Type (2021-2032) Figure 68. Global Radiopharmaceuticals in Nuclear Medicine Price (US$/Unit) by Type (2021-2032) Figure 69. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2021-2032) Figure 70. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Application (2021-2032) Figure 71. Global Radiopharmaceuticals in Nuclear Medicine Price (US$/Unit) by Application (2021-2032) Figure 72. Radiopharmaceuticals in Nuclear Medicine Value Chain Figure 73. Radiopharmaceuticals in Nuclear Medicine Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Radiopharmaceuticals in Nuclear Medicine Industry Opportunities and Challenges

Scope & coverage.

Types
  • Diagnostic Radiopharmaceuticals
  • Therapy Radiopharmaceuticals
Applications
  • Oncology
  • Cardiology
  • Other
Companies covered
  • Aurobindo Pharma
  • Bracco Imaging
  • Cardinal Health
  • Curium Pharma
  • GE Healthcare
  • Jubilant Pharma
  • Lantheus
  • Mundipharma
  • Novartis
  • SIEMENS
  • Bayer
  • Dongcheng
  • Eli Lilly
  • China Isotope & Radiation

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size (2021-2032)
  4. 2.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales (2021-2032)
  5. 2.2.3 Global Radiopharmaceuticals in Nuclear Medicine Market Average Price (2021-2032)
  6. 2.3 Radiopharmaceuticals in Nuclear Medicine by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Diagnostic Radiopharmaceuticals
  9. 2.3.3 Therapy Radiopharmaceuticals
  10. 2.4 Radiopharmaceuticals in Nuclear Medicine by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Oncology
  13. 2.4.3 Cardiology
  14. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Radiopharmaceuticals in Nuclear Medicine Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Radiopharmaceuticals in Nuclear Medicine Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Radiopharmaceuticals in Nuclear Medicine Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Radiopharmaceuticals in Nuclear Medicine, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Radiopharmaceuticals in Nuclear Medicine, Product Type & Application
  8. 3.8 Global Manufacturers of Radiopharmaceuticals in Nuclear Medicine, Established Date
  9. 3.9 Global Radiopharmaceuticals in Nuclear Medicine Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Aurobindo Pharma
  2. 4.1.1 Aurobindo Pharma Company Information
  3. 4.1.2 Aurobindo Pharma Business Overview
  4. 4.1.3 Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  6. 4.1.5 Aurobindo Pharma Recent Developments
  7. 4.2 Bracco Imaging
  8. 4.2.1 Bracco Imaging Company Information
  9. 4.2.2 Bracco Imaging Business Overview
  10. 4.2.3 Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  12. 4.2.5 Bracco Imaging Recent Developments
  13. 4.3 Cardinal Health
  14. 4.3.1 Cardinal Health Company Information
  15. 4.3.2 Cardinal Health Business Overview
  16. 4.3.3 Cardinal Health Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Cardinal Health Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  18. 4.3.5 Cardinal Health Recent Developments
  19. 4.4 Curium Pharma
  20. 4.4.1 Curium Pharma Company Information
  21. 4.4.2 Curium Pharma Business Overview
  22. 4.4.3 Curium Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Curium Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  24. 4.4.5 Curium Pharma Recent Developments
  25. 4.5 GE Healthcare
  26. 4.5.1 GE Healthcare Company Information
  27. 4.5.2 GE Healthcare Business Overview
  28. 4.5.3 GE Healthcare Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 GE Healthcare Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  30. 4.5.5 GE Healthcare Recent Developments
  31. 4.6 Jubilant Pharma
  32. 4.6.1 Jubilant Pharma Company Information
  33. 4.6.2 Jubilant Pharma Business Overview
  34. 4.6.3 Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  36. 4.6.5 Jubilant Pharma Recent Developments
  37. 4.7 Lantheus
  38. 4.7.1 Lantheus Company Information
  39. 4.7.2 Lantheus Business Overview
  40. 4.7.3 Lantheus Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Lantheus Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  42. 4.7.5 Lantheus Recent Developments
  43. 4.8 Mundipharma
  44. 4.8.1 Mundipharma Company Information
  45. 4.8.2 Mundipharma Business Overview
  46. 4.8.3 Mundipharma Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Mundipharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  48. 4.8.5 Mundipharma Recent Developments
  49. 4.9 Novartis
  50. 4.9.1 Novartis Company Information
  51. 4.9.2 Novartis Business Overview
  52. 4.9.3 Novartis Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Novartis Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  54. 4.9.5 Novartis Recent Developments
  55. 4.10 SIEMENS
  56. 4.10.1 SIEMENS Company Information
  57. 4.10.2 SIEMENS Business Overview
  58. 4.10.3 SIEMENS Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 SIEMENS Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  60. 4.10.5 SIEMENS Recent Developments
  61. 4.11 Bayer
  62. 4.11.1 Bayer Company Information
  63. 4.11.2 Bayer Business Overview
  64. 4.11.3 Bayer Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Bayer Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  66. 4.11.5 Bayer Recent Developments
  67. 4.12 Dongcheng
  68. 4.12.1 Dongcheng Company Information
  69. 4.12.2 Dongcheng Business Overview
  70. 4.12.3 Dongcheng Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Dongcheng Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  72. 4.12.5 Dongcheng Recent Developments
  73. 4.13 Eli Lilly
  74. 4.13.1 Eli Lilly Company Information
  75. 4.13.2 Eli Lilly Business Overview
  76. 4.13.3 Eli Lilly Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Eli Lilly Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  78. 4.13.5 Eli Lilly Recent Developments
  79. 4.14 China Isotope & Radiation
  80. 4.14.1 China Isotope & Radiation Company Information
  81. 4.14.2 China Isotope & Radiation Business Overview
  82. 4.14.3 China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Product Portfolio
  84. 4.14.5 China Isotope & Radiation Recent Developments
5 Global Radiopharmaceuticals in Nuclear Medicine Market Scenario by Region
  1. 5.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region: 2021-2032
  3. 5.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region: 2021-2026
  4. 5.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region: 2027-2032
  5. 5.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region: 2021-2032
  6. 5.3.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region: 2021-2026
  7. 5.3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region: 2027-2032
  8. 5.4 North America Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country
  9. 5.4.1 North America Radiopharmaceuticals in Nuclear Medicine Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2032)
  11. 5.4.3 North America Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country
  16. 5.5.1 Europe Radiopharmaceuticals in Nuclear Medicine Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2032)
  18. 5.5.3 Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country
  41. 5.7.1 South America Radiopharmaceuticals in Nuclear Medicine Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2032)
  43. 5.7.3 South America Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2021-2032)
  2. 6.1.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2021-2032)
  4. 6.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2021-2032)
  5. 6.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Radiopharmaceuticals in Nuclear Medicine Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2021-2032)
  2. 7.1.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2021-2032)
  4. 7.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2021-2032)
  5. 7.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Radiopharmaceuticals in Nuclear Medicine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Radiopharmaceuticals in Nuclear Medicine Value Chain Analysis
  2. 8.1.1 Radiopharmaceuticals in Nuclear Medicine Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Radiopharmaceuticals in Nuclear Medicine Production Mode & Process
  5. 8.2 Radiopharmaceuticals in Nuclear Medicine Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Radiopharmaceuticals in Nuclear Medicine Distributors
  8. 8.2.3 Radiopharmaceuticals in Nuclear Medicine Customers
9 Global Radiopharmaceuticals in Nuclear Medicine Analyzing Market Dynamics
  1. 9.1 Radiopharmaceuticals in Nuclear Medicine Industry Trends
  2. 9.2 Radiopharmaceuticals in Nuclear Medicine Industry Drivers
  3. 9.3 Radiopharmaceuticals in Nuclear Medicine Industry Opportunities and Challenges
  4. 9.4 Radiopharmaceuticals in Nuclear Medicine Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst